Pregnancy
Interview: predicting pregnancy complications before they happen
The founders of Mirvie are tapping into their expertise in RNA science and oncology to address gaps in maternal health with a platform that can predict pregnancy complications, such as preeclampsia, before they happen.
With 46,000 maternal deaths and 500,000 fetal or newborn deaths related to preeclampsia every year globally, there is an urgent need to tackle the burden of pregnancy complications.
Mirvie was founded to do just that, with the development of an RNA platform that can predict pregnancy complications before they happen.
RNA-based diagnostics utilise RNA molecules as indicators of disease or other conditions. Created over seven years, the platform uses a blood test to analyse RNA messages that impact pregnancy, revealing the unique biology of each one.
The platform has analysed over 15,000 pregnancies to date, and has been involved in several clinical studies, where it has been found to predict 90 per cent of pregnancies at risk of preterm preeclampsia and 60 per cent of babies with severe foetal growth restriction months in advance of delivery.
With plans for further research and to expand its global reach, Mirvie co-founder Maneesh Jain says the platform has the power to transform how we predict, prevent and treat unexpected complications.
Supporting pregnancy journeys
Jain and co-founder Stephen Quake founded Mirvie following their own pregnancy journeys, through which they discovered how quickly a routine pregnancy can result in an emergency C-section and a preterm birth.
“We wanted to make a difference for the next generation, because this is an area that has been left behind,” Jain tells Femtech World.
“There are some tests on the market that, once you are hospitalised with symptoms of preeclampsia, can diagnose if you are going to progress to a more severe disease or not.
“The challenge is that we don’t have any tests to predict and prevent the condition in the first place. So, our focus is preventive care, because once people develop symptoms, it’s too late.
“We can implement interventions such as delivering the baby early to save the mother, but that has a lot of adverse outcomes for both the mother and baby. I think moving to a preventive care paradigm is paramount in our minds.”
Preeclampsia is estimated to affect two to eight per cent of pregnancies worldwide, leading to 46,000 maternal deaths per year, and around 500,000 fetal or newborn deaths, according to the World Health Organisation.
“The statistics are pretty staggering, and preeclampsia is a challenging condition,” says Jain.
“We started with preeclampsia because it affects both the mother and the baby. There’s so much research now showing that if you have preeclampsia in pregnancy, it’s not just the childbirth process; it’s decades after that, you have a much higher risk of heart disease and stroke. So it’s really important to try to prevent these conditions in the first place, and so that’s our focus – to use our platform to detect molecular signatures of the condition.”
The platform is supported by a group of experts and is used in conjunction with a preventative care plan for pregnancies that have been flagged as at-risk.
“The preventive care plan includes medication and monitoring,” says Jain. “It may not in all cases stop the disease, but it certainly delays the onset of the condition, which is very helpful, because then the baby can be developing closer to term, and the mother can have less severe forms of disease.”
Harnessing RNA
Drawing from their background in advanced RNA science and oncology, where they had previously developed blood tests to detect cancer at the earliest stages, the pair wanted to make a difference to the modern pregnancy journey.
“Often, the approach to pregnancy is to hope for the best, and we’re largely in the dark on how things are developing,” says Jain.
“We used our background from oncology, using the idea that you can utilise RNA to tap into biology in a non-invasive manner and get a sense of what’s happening with the pregnancy.
“By looking at RNA, we can get an insight into how the development is proceeding and if it’s on track, or if it’s off track. What’s amazing is that we can now do it non-invasively with just a simple blood sample from the mother – you’re not taking a piece of the placenta or any tissue.”
Through its clinical research with a team of international collaborators, Mirvie showed that the RNA analysis could predict gestational age.
“Just by looking at the RNA signature in regular pregnancies, you can predict how far along you are,” explains Jain.
“Of course, we do it today with an ultrasound. But this finding was important because it showed that, with normal pregnancies, RNA is tracking the development very closely, and it can predict how far along you are.
“If there isn’t a predictable and changing pattern of RNA in normal pregnancies, then you really can’t look for deviations from that pattern.”
Jain says the test is already available in the US and can be obtained through telemedicine approval, with mobile phlebotomists that can take blood draws, which Mirvie then runs in its lab.
“We report the result to the patient, most often also to their treating OBGYN, and then if they happen to be positive, we put the action plan in place right away,” Jain says.
Mirvie now plans to expand globally and carry out further studies to help obtain insurance coverage for the platform.
“It seems there is a lot more innovation starting to happen in maternal health, and it’s much needed,” says Jain.
“Having worked across a few areas of medicine, I believe that this may be one of the greatest unmet medical needs that we have today, because the impact is lifetime for the mother, the baby, and the family.
“One of the things that is so important is awareness in this field, and to have more awareness of innovations in maternal health. I think that will change how much research is being done, how much investment is coming in, and how much better solutions we have that can truly advance the field.”
Mirvie was the winner of the Femtech World Maternal Health Innovation of the Year Award 2025. See the full winners list here.
Type 2 diabetes diagnoses are rising twice as fast in women under 40 as in women over 40, new data shows.
Type 2 diabetes is a serious condition and can lead to complications such as heart attacks and strokes. When it develops in younger people, it can be more aggressive and have more severe and acute effects.
Diagnoses in women under 40 rose by 47 per cent between 2017/18 and 2023/24. By comparison, diagnoses rose by 22 per cent in women aged 40 to 79.
During the same period, type 2 diabetes diagnoses in men under 40 increased by 34 per cent.
Diabetes UK said it is concerned about the follow-up care offered to women who have had gestational diabetes, also known as GDM, which increases the risk of developing type 2 diabetes after pregnancy.
Gestational diabetes is high blood sugar that develops during pregnancy and usually goes away after birth, but it raises the risk of type 2 diabetes later.
Colette Marshall, chief executive at Diabetes UK, said: “These figures should be a wake-up call. Type 2 diabetes is rising twice as fast in younger women compared to older women, and a crucial opportunity for prevention is being missed. Every diagnosis is life-changing, but when it develops in younger people, type 2 diabetes is even more aggressive.
“Pregnancy shouldn’t be a pathway to ill health. Yet despite facing a much higher risk of type 2 diabetes, too many women with GDM receive little or no follow-up care after pregnancy.
“As the Government turns its Strategy into action, support for women who have had gestational diabetes must not be overlooked.”
Last year, the NHS published the first national GDM audit for England in 2024/25, which revealed inconsistencies in follow-up care.
Only 57 per cent of women with GDM received an annual HbA1c test, which should be offered to every woman with GDM.
An HbA1c test measures average blood sugar levels over the previous two to three months.
Only 4.5 per cent of women had received support through the NHS Diabetes Prevention Programme.
The report also found that 11 per cent of women developed prediabetes within five years of having GDM, while 15 per cent developed type 2 diabetes within 10 years.
Prediabetes means blood sugar levels are higher than normal and a person has a higher risk of developing type 2 diabetes.
A recent survey funded by Diabetes UK also found that more than a third of women with GDM felt abandoned by healthcare services after giving birth.
If you live in England and have had gestational diabetes, you can self-refer to the NHS Diabetes Prevention Programme, which supports people at risk of developing type 2 diabetes. If you live in Northern Ireland, Scotland or Wales, you can speak to your GP about support.
Diabetes UK has written to women’s health minister Baroness Merron calling for urgent improvements to postnatal support for those diagnosed with GDM during pregnancy.
GDM affects between 10 and 20 per cent of pregnant women, but Diabetes UK said cases have long been underreported and UK-wide data on the condition has not been readily available.
The charity said poor follow-up care for women who have had GDM may be contributing to rising rates of type 2 diabetes in younger women.
It is calling for consistent postnatal follow-ups for women after GDM, more referrals to the NHS Diabetes Prevention Programme, greater accountability for improvements in postnatal care, and action on inequalities affecting women from deprived and minority ethnic communities.
System C has completed the national rollout of BadgerNet Maternity across all seven NHS Health Boards in Wales. This is the first time any UK nation has unified its maternity care under a single digital record and patient-facing app.
With approximately 26,000 babies born annually in Wales, BadgerNet connects maternity information across organisational boundaries in the country.
Expectant parents can access their records, maternity appointments and key updates digitally through a single app, wherever they receive care while clinicians have secure access to the right information at the point of care.
The national three-year agreement across all Heath Boards replaces a patchwork of separate local systems and eliminates the need for paper hand-held notes.
Anthony Tracey is director of digital at Hywel Dda University Health Board, the final of the Welsh Health Boards to go live with BadgerNet.
He said: “The rollout of BadgerNet across Wales is a vitally important step forward in modernising our maternity services and providing a consistent service across the country.
“By giving expectant parents direct access to their information and enabling clinicians to share data more effectively, we are strengthening safety, transparency and consistency in maternity care nationwide.”
For expectant parents, the single digital maternity record transforms how they engage with their care.
Instead of carrying paper notes and repeating information at every appointment, parents can access key details, appointments and updates digitally, supporting more informed conversations and shared decision-making.
The result is greater transparency, fewer administrative frustrations and a more joined-up experience throughout pregnancy and into the postnatal period, regardless of which health board they fall under.
For clinicians and Health Boards, the joined-up approach reduces duplication and streamlines handovers across teams and sites. Information is digitally captured once and made available securely wherever it is needed, helping to minimise errors, reduce time spent tracking down notes and support more efficient multidisciplinary working.
At a national level, linking maternity data across Wales creates a foundation for safer, more consistent care.
Aggregated, standardised information enables earlier identification of trends and variation, supports evidence-based policy decisions and enhances long-term service planning.
With a comprehensive view of maternity activity and outcomes across the country, Wales is now better positioned to raise standards for parents, babies and families.
Guy Lucchi, managing director of healthcare at System C, added: “Delivering a truly national approach across all seven Health Boards is a significant achievement for Wales.
“One shared system means information flows with the patient, not the organisation.
“That reduces duplication, supports earlier identification of risk and frees up valuable clinical time.
“Crucially, linking maternity data at a national level provides powerful insight to drive improvement. Health Boards can benchmark, plan services with greater confidence and ensure resources are targeted where they are needed most, while expectant parents benefit from clearer communication and a more connected experience of care.”
Early birth may cut serious complications and stillbirth risk in high blood pressure pregnancies without increasing caesarean rates, a Cochrane review suggests.
Planned early birth after 34 weeks cut serious maternal complications by nearly half compared with watchful waiting, the findings suggest.
It also likely reduced the risk of stillbirth by about 75 per cent, although the authors said this should be interpreted with caution.
Catherine Cluver, senior author of the review and researcher at Stellenbosch University and Tygerberg Hospital, said: “These findings give clinicians and women clearer guidance about the timing of birth when high blood pressure develops in pregnancy.
“For women with pre-eclampsia in particular, the evidence supports offering planned early birth from 34 weeks, and no later than 37 weeks.”
This Cochrane review, led by King’s College London, pooled data from six randomised controlled trials involving 3,491 women.
The trials compared planned early birth after 34 weeks with watchful waiting in women with one or more hypertensive disorders of pregnancy.
Hypertensive disorders of pregnancy, including pre-eclampsia, gestational hypertension and chronic hypertension, are the second leading cause of maternal death globally.
For women with pre-eclampsia, early birth remains the only definitive treatment, as the condition is driven by the placenta and will only resolve once it is delivered.
The trials took place in the Netherlands, UK, US, India and Zambia.
The review found high-certainty evidence that serious maternal complications were nearly halved in women who had planned early birth compared with those managed with watchful waiting.
The finding on stillbirth was based on moderate-certainty evidence and was driven by a single trial in India and Zambia, where stillbirth rates are higher. No stillbirths were recorded in the high-income country trials.
The review also found that planned early birth likely does not increase neonatal unit admission, although this finding was also based on moderate-certainty evidence.
The authors said the maternal benefit held across both high- and low-income settings, suggesting early birth reduces complications even when women are already receiving appropriate monitoring and care.
Alice Beardmore-Gray, lead author of the review and obstetrician at King’s College London, said: “Judging when to offer birth is the question that we battle with clinically every day.”
The authors added that in two of the trials, more than half the women allocated to watchful waiting ended up needing emergency birth before 37 weeks.
They typically gave birth just three to five days later than women allocated to planned early birth and often experienced more complications.
Beardmore-Gray said: “A common misconception is that by waiting longer, mum and baby are gaining more time, but often what you are doing is just delaying an inevitable emergency birth, when both may be in a worse condition.”
The review found high-certainty evidence of no increased risk of caesarean section associated with planned early birth.
Beardmore-Gray said: “That is the first question anyone asks when you offer them an early induction: won’t it increase my risk of a C-section?
“Being able to clearly answer no is a really important piece of information to give women when counselling them about the timing of their birth.”
The authors said the timing of birth should take into account the woman’s preferences and the severity of her condition.
They said these findings are consistent with and reinforce current international guidelines, which recommend that all women with pre-eclampsia should be offered planned early birth no later than 37 weeks.
Women with gestational hypertension or chronic hypertension without severe features may choose to continue with careful monitoring, with planned early birth considered from 39 weeks onwards.
Further research is needed on longer-term outcomes for infants born late preterm and on the long-term cardiovascular health of mothers affected by hypertensive disorders of pregnancy.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Hormonal health2 weeks agoNHS urged to update website following renaming of PCOS
Events4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Entrepreneur1 week agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
Diagnosis4 weeks agoArtera receives FDA Clearance for breast cancer platform